Effox: Navigating Long-Term Cardiovascular Care

In the realm of cardiovascular health, understanding the medications prescribed is crucial for informed decision-making. One such medication, Effox, containing the active substance isosorbide mononitrate, plays a vital role in the long-term treatment of various cardiovascular conditions. This comprehensive guide aims to simplify the information provided in the Patient Information Leaflet (PIL), making it accessible to individuals seeking a deeper understanding of Effox.

Decoding the Composition

Effox tablets contain 40 mg of isosorbide mononitrate (INN), along with other ingredients such as lactose monohydrate, microcrystalline cellulose, potato starch, talc, colloidal silicon dioxide, and aluminium stearate.

Therapeutic Indications

Effox is prescribed for the long-term treatment of the following conditions:

  1. Coronary Artery Disease (CAD): Effox provides sustained care for the health of coronary arteries.
  2. Angina Pectoris: It is used for both treatment and prevention, even after a treated myocardial infarction.
  3. Chronic Heart Failure: Effox, when combined with cardiac glycosides, diuretics, ACE-inhibitors, or arterial vasodilators, contributes to the long-term management of chronic heart failure.
  4. Pulmonary Hypertension: Effox plays a role in managing elevated blood pressure in the pulmonary arteries.

Posology and Mode of Administration

Effox is administered orally, with the recommended dosage being 1 tablet daily or twice daily without chewing and with a sufficient amount of fluid. If prescribed twice daily, the second dose should be taken 8 hours after the first dose. Importantly, there is no evidence to suggest an adjustment of the dosage in elderly patients.

To take a tablet, place it with the partition upward on a hard surface and apply slight thumb pressure.

Contraindications: When to Exercise Caution

Certain conditions warrant caution, and Effox should not be used in the following cases:

  • Hypersensitivity: Individuals allergic to isosorbide mononitrate, other nitro compounds, or other ingredients.
  • Cardiogenic Shock: Unless a sufficient end-diastolic pressure is maintained by appropriate measures.
  • Acute Circulatory Failure: In cases of shock or collapse.
  • Severe Hypotension: When systolic pressure is less than 90 mm Hg.
  • Concurrent Use with Phosphodiesterase Inhibitors: Especially during nitrate therapy, such as sildenafil.

Special Warnings and Precautions

Effox should be used with particular caution and under medical supervision in specific conditions, including:

  • Hypertrophic Obstructive Cardiomyopathy
  • Constrictive Pericarditis
  • Cardiac Tamponade
  • Low Filling Pressures: In conditions like acute myocardial infarction and impaired left ventricular function (left ventricular failure).
  • Aortic and/or Mitral Stenosis
  • Diseases associated with an increased intracranial pressure
  • Orthostatic Dysfunction

The onset of action of Effox is not sufficiently rapid to treat an acute anginal attack. The development of tolerance and cross-tolerance towards other nitrate-type drugs has been described. To prevent a decrease in, or loss of, effect, continuously high dosages should be avoided.

Patients undergoing maintenance treatment with Effox should be informed not to use phosphodiesterase inhibitors (e.g., sildenafil)-containing products. Effox therapy should not be interrupted to take phosphodiesterase inhibitors, as it could increase the risk of inducing an attack of angina pectoris.

For reasons of particular caution, isosorbide mononitrate should be used only at a physician’s special order during pregnancy and lactation, as there is no sufficient experience with its use in pregnant or nursing women. Animal experiments have not yielded any indication of fetal damage.

Interactions with Other Medicaments and Forms of Interaction

Concurrent intake of drugs with blood pressure-lowering properties, such as beta-blockers, calcium channel antagonists, vasodilators, and/or alcohol, may potentiate the hypotensive effect of Effox. This interaction might also occur with neuroleptics and tricyclic antidepressants. Effox’s blood pressure-lowering effect will be increased if used together with phosphodiesterase inhibitors (e.g., sildenafil) used for erectile dysfunction. This combination could lead to life-threatening cardiovascular complications, emphasizing the importance of patients on Effox therapy avoiding phosphodiesterase inhibitors.

Reports suggest that when administered concomitantly, Effox may increase the blood level of dihydroergotamine and its hypertensive effect. Effox may also affect the patient’s reactivity to an extent that their ability to drive or operate machines is impaired. This effect is increased in combination with alcohol.

Undesirable Effects: Understanding Side Effects

A very common (>10% of patients) adverse reaction to Effox is headache. The incidence of headache diminishes gradually with time and continued use. At the start of therapy or when the dosage is increased, hypotension and/or light-headedness on standing are commonly observed (i.e., in 1-10% of patients). These symptoms may be associated with dizziness, drowsiness, reflex tachycardia, and a feeling of weakness.

Uncommonly (i.e., in less than 1% of patients), nausea, vomiting, flush, and allergic skin reactions (e.g., rash), which may be sometimes severe, may uncommonly occur. In single cases, exfoliative dermatitis may occur. Very rare Stevens-Johnson Syndrome may occur. Angioedema is observed in very rare cases. Severe hypotensive responses have been reported for organic nitrates and include nausea, vomiting, restlessness, pallor, and excessive perspiration. Uncommonly, collapse may occur (sometimes accompanied by bradyarrhythmia and syncope). Uncommonly, severe hypotension may lead to enhanced angina symptoms.

A few reports on heartburn, most likely due to a nitrate-induced sphincter relaxation, have been recorded. During the treatment with Effox, a temporary hypoxemia may occur due to a relative redistribution of the blood flow in hypoventilated alveolar areas. Particularly in patients with coronary artery disease, this may lead to myocardial hypoxia.

Practical Tips and Advice for Patients

To ensure the safe and effective use of Effox, patients are advised to:

  • Adhere to Prescribed Dosages: Take the medication as prescribed by the healthcare provider.
  • Avoid Phosphodiesterase Inhibitors: Patients on Effox therapy should avoid medications containing phosphodiesterase inhibitors, such as sildenafil.
  • Communicate Any Concerns: If any side effects or concerns arise, patients should promptly communicate with their healthcare provider.
  • Storage: Keep Effox out of the reach of children and store it at room temperature not exceeding 30°C.


Effox stands as a crucial medication in the domain of cardiovascular health. Understanding its composition, therapeutic indications, and potential interactions empowers individuals to use it responsibly under medical guidance. Patients should adhere to prescribed dosages, be aware of possible side effects, and communicate any

concerns to their healthcare provider. By incorporating Effox into a comprehensive cardiovascular care plan, individuals can strive towards long-term heart health and well-being.